ONCOLOGY

Lankenau Medical Center Cancer Program

Annual Report based on 2009 Statistics

Lankenau Medical Center
Main Line Health

Message from the Chairman of the Cancer Committee

On behalf of the Lankenau Medical Center Cancer Committee, I am pleased to present the Annual Report 2010. Our dedicated team of physicians, nurses, data managers, social workers and physical therapists work tenaciously in pursuit of higher levels of excellence and best practices. We have met the challenge and goal of delivering the highest standard of care to our patients through the availability of online resources, educational literature and community programs. The committee recognizes the need for ongoing and sustainable programmatic and quality improvements. Performance measures are monitored using the American College of Surgeons Commission on Cancer and the Society of Thoracic Surgery databases. In addition, in-house variable matrices have been developed by our sub-committees to monitor quality.

Each year, we highlight a specific oncologic disease site to demonstrate our commitment to delivering the highest level of safe, quality care to all cancer patients. The Lankenau Lung Cancer Program provides cutting edge treatment of lung cancer with prevention and screening efforts, research endeavors, and advanced surgical therapies. The Lankenau Lung Cancer Center, established in 1996, utilizes a collaborative process whereby clinical staff review complicated patients with lung cancer on a weekly basis. The talented multi-disciplinary team is comprised of Pulmonary Medicine, Medical Oncology, Radiation Oncology and Thoracic Surgery physicians as well as nursing and clinical trial protocol office staff. Since becoming a smoke-free campus in 2008, ongoing smoking cessation classes for our employees and patients are an important opportunity for lung cancer prevention. One strategy for growth in the coming year includes a screening program initiative for high risk patients with the goal of identifying early stage lung cancers.

During 2010, Lankenau Medical Center celebrated major milestones and accomplishments through enhancement of the physical environment and clinical capabilities to meet the needs of our patients. With the opening of The Comprehensive Breast Center in May, patients are now screened, evaluated and treated in a comfortable and serene space reflecting the priority we place on addressing this critical health concern for women. Supporting the Breast Center, located in the medical center, is a state-of-the-art 16-channel 1.5 Tesla MRI with breast biopsy capability. The new advanced Endoscopy Suite allows clinicians to perform minimally invasive curative resections in the earliest stages of esophageal, gastric, duodenal and rectal cancers and enhances diagnostic capabilities in these disease sites. The installation of a true beam linear accelerator will allow the administration of extra-cranial stereotactic radiation to patients with recurrent malignancies. The linear accelerator treats malignancies with higher doses of radiation while sparing normal tissues and benefits patients by minimizing adverse side effects.

The Lankenau Medical Center Cancer Committee is committed to another year of a comprehensive, focused effort toward reaching our goals. We will continue to integrate new technology, advances through clinical trials and quality improvements. We are dedicated to enhancing basic science research through strengthening ties with the Lankenau Institute for Medical Research.

I am proud to represent Lankenau in my role as Chairman of the Cancer Committee and even prouder to work with the talented and committed professionals who strive to take cancer care to the next level.

Ned Z. Carp, MD

Chairman of the Cancer Committee;
Pennsylvania State Chairman to the Commission on Cancer of the American College of Surgeons;
Member, Commission on Cancer

Lankenau Medical Center Cancer Clinical Trials Program

Cancer clinical trials evaluate new approaches to cancer treatment and prevention by providing patients at all stages of cancer with cutting edge strategies. This may involve surgery, chemotherapy, radiation therapy, biologic therapy, or a combination of these modalities. Since 1994, the cancer program at Lankenau has been providing access to National Cancer Clinical Trials as a component of the Main Line Health CCOP: Cancer Clinical Trials Program. A CCOP is a National Cancer Institute (NCI) sponsored Cancer Clinical Trials Program. Our Main Line Health CCOP program is one of only 50 in the nation. 2009 marks the 16th year of our NCI grant, which gives our patients access to nationally recognized cancer clinical trials right where they live. Our CCOP program is affiliated with the following research bases: Eastern Cooperative Oncology Group (ECOG); Gynecologic Oncology Group (GOG); MD Anderson Cancer Center; National Surgical Adjuvant Breast and Bowel Project (NSABP); Radiation Therapy Oncology Group (RTOG), and Wake Forest Comprehensive Cancer Center.

The Cancer Program at Lankenau Medical Center also participates in pharmaceutical sponsored clinical trials, investigator initiated research, and other national research organizations including the American College of Surgeons Oncology Group (ACOSOG).

As a research center, Lankenau clinicians are also involved in several innovative research collaborations with the basic scientists of the Lankenau Institute for Medical Research (LIMR). This is the premiere of how basic science discovery is translated into patient care.

More than 85% of cancer patients are diagnosed and treated in their local communities. We are empowering our community by providing access to state of the art therapy in our fight against cancer.

Maria Hendricks, MSN, RN, CCRP
Administrator, Main Line Health CCOP: Cancer Clinical Trials Program

Report on Lung Cancer | 2009

Lung cancer remains the single largest cause of cancer mortality in the United States. In 2009, there were an estimated 219,440 new cases and a predicted 159,390 deaths from this disease. Unfortunately, most patients present to their physicians with late stage disease, due in part to a lack of an acceptable screening tool. CT scan screening is showing promise with a pivotal trial hopefully being published later this year to analyze the benefit of CT screening in patients 55-74 years of age who have smoked 30 pack years or more of tobacco.

In 2009, we evaluated 147 patients with lung cancer at the Lankenau Medical Center. Of these, 132 patients were considered analytical cases, indicating that they were either diagnosed and/or administered any of their first course of treatment at LMC. Approximately, 95% of our patients were diagnosed and/or treated for non-small-cell lung cancer (NSCLC) and the remaining 5% for small-cell lung cancer (SCLC), which is in keeping with the national statistics.

The observed survival breakdown by best CS-AJCC stage can be seen below. Compared against the NCDB statistics reported for observed survival (based on data from 71 programs in PA) we find that our survival rates are comparable, and in some instances superior to the state and national figures, see Combined-Graph 1.

We continue to participate with the NCI-sponsored CCOP research grant. This allows us to have clinical trials for all stages of lung cancer. Our team is also collaborating very closely with the Lankenau Institute for Medical Research (LIMR), doing basic science research regarding the role of inflammation in the development of lung cancer. Our Multi-disciplinary Lung Center was established in 1996 and continues to function at a high level, reviewing complicated patient cases on a weekly basis. This multi-disciplinary team consists of members from Pulmonary Medicine, Medical Oncology, Radiation Oncology, Thoracic Surgery, Nursing and our Clinical Trials Protocol team. The Center has allowed us to quickly evaluate patients, provide therapeutic options to the patient and family, and move on to treatment in a more timely progression.

Our monthly Pulmonary Tumor Board conferences continue to gather a multi-disciplinary audience including Pulmonary Medicine, Surgical Oncology, Medical Oncology, Radiation Oncology, Thoracic Surgery, Radiology, Pathology, as well as the remainder of our medical community including interested basic science researchers from LIMR. This conference has been instrumental in spreading information among our team and in discussing future directions on research and patient care.

In the upcoming years, we hope to initiate screening for lung cancer with CT scanning, as well as lung cancer prevention initiatives, such as our continued efforts with tobacco cessation. Our goal as a multi-disciplinary team is to continue with the highest quality evaluation and therapy for our patients.

Thomas J. Meyer, MD, FCCP, ABSM
Pulmonary Diseases
Medical Director Lung Center

Lung Cases Dx 2001-2005
Observed Survival by Best CS-AJCC Stage





Oncology Data Services

The Oncology Data Services (ODS) Department at Lankenau Medical Center manages, analyzes and reports data on persons with a diagnosis or treatment of cancer and benign brain and CNS tumors. The data includes a wide range of demographic and medical and treatment information.

In 2009, 1,243 cases were abstracted and added to our database. Of the 1,243 cases, 1,084 were analytic (newly diagnosed and/or initially treated at LMC). There were 159 non-analytic patients seen for subsequent treatment or recurrence and/or diagnosed in physicians' offices.

Our database now contains information on 11,269 patients. Maintaining this data ensures that the medical staff, and administration have accurate and timely information for treatment, studies, research, audits, and educational purposes.

The five most frequent sites for 2009 were breast, colorectal, lung, prostate, and uterine.

As an important part of an approved Teaching Hospital Cancer Program (THCP) of The American College of Surgeon's Commission on Cancer, the Oncology Data Specialists are experts who capture a complete summary of the patient's medical history, diagnostic findings, cancer information, cancer therapy, and follow-up status. The Oncology Data Specialist is also responsible for reporting cancer incidence to the State and National agencies as required by law for use in treatment and prevention studies; coordinating cancer conferences for medical education, quality improvement studies and outcomes analysis reporting. This allows Lankenau to compare practices with national standards. The staff also provides incidence reporting to physicians and administration, and processes requests for specialized studies.

The evidenced-based medicine of today recognizes the skills and abilities of the Oncology Data Specialists. The evolution of Cancer Information Management and the utilization of oncology data experts at every level of cancer surveillance continue to ring true. The closeout of the 2009 accession year marked the beginning of a new phase of data capturing. With the forthcoming changes from the Commission on Cancer (CoC) and other standard-setters, our staff continues to make accommodations for the new and/or revised coding/staging rules, effective for cases diagnosed 01/01/2010 and after. Our staff is highly trained in the knowledge of medical sciences, programming, and data retrieval and analysis. The department is currently staffed with two Oncology Data Specialists that attend educational programs to maintain certification to keep up-to-date with the latest changes and advancements in the oncology field.

Sharon L Nutter, RHIA, CTR
Oncology Data Specialist

Site Distribution Report—AJCC Staging for Lankenau Medical Center

Study Group: **2009 Analytic Cases (newly diagnosed)**		**AJCC Stage**										
Primary Site	**Cases**	**0**	**1**	**2**	**3**	**4**	**N/A**	**Unk**	**Male**	**Female**	**% LMC Database**	**ACS Est. Figures***
Anus	10	1	0	3	0	0	1	5	4	6		
Bladder	30	18	4	6	0	2	0	0	18	12		
Bones/Joints	4	0	0	0	0	0	0	4	3	1		
Breast	268	60	103	65	16	7	1	16	4	264	25%	13%
Cervix	15	0	10	1	1	2	0	1	0	15		
Colon/Rectum	138	10	34	34	42	12	1	5	73	65	13%	10%
Esophagus	9	1	2	1	1	1	0	3	5	4		
Gallbladder	4	0	2	2	0	0	0	0	2	2		
Kidney	17	1	10	1	2	3	0	0	15	2		
Larynx	3	0	2	0	0	0	0	1	3	0		
Leukemia/Hematopoietic	18	0	0	0	0	0	18	0	9	9		
Lip and Oral Cavity	10	1	0	0	2	4	0	3	7	3		
Liver	7	0	3	0	1	2	0	1	5	3		
Lung	132	5	36	7	31	39	1	13	61	71	12%	15%
Lymphoma	27	0	11	2	5	6	0	3	19	8		
Melanoma	56	18	20	3	2	2	0	11	30	26		
Myeloma	20	0	0	0	0	0	20	0	11	9		
Other	21	1	3	3	0	1	7	6	12	8		
Ovary	33	0	8	4	12	6	2	1	0	33		
Pancreas	21	0	2	9	1	3	0	6	7	14		
Peritoneum/omentum/mesentery	4	0	0	0	0	0	4	0	0	4		
Prostate	88	0	0	75	6	5	0	2	88	0	8%	13%
Soft Tissue	5	0	0	0	1	0	0	4	2	3		
Stomach	15	0	4	2	0	5	0	4	12	3		
Thyroid	14	0	9	1	1	1	0	2	2	12		
Unknown Primary	28	0	0	0	0	0	28	0	11	17		
Uterus	75	2	51	6	8	2	3	3	0	75	7%	3%
Vulva	12	6	1	1	2	0	0	2	0	12		
Total	**1,084**	**124**	**315**	**226**	**134**	**103**	**86**	**96**	**403**	**681**		

The most frequent cancer sites for 2009 are highlighted in the above table and represent the percentage of cancer incidence seen at Lankenau Medical Center as compared to the American Cancer Society's national estimates. They are in descending order: Breast, Prostate, Colorectal, Lung, and Uterine.

In addition, 159 patients were diagnosed in physicians' offices or elsewhere and treated for ongoing disease at Lankenau Medical Center for a total of 1,243 cases.

*Cancer Facts & Figures 2009, American Cancer Society [1]B/B-Benign/Borderline

Lankenau Medical Center Cancer Committee—2009/2010

Ned Carp, MD	**Chairman, ACoS Liaison/CoC State Chair**
Gary Antonelli, MS, RT, (R) (T)	Radiation Oncology
Robert L Benz, MD	Administration/Nephrology
Carol DeBakker, MD	Physical Medicine and Rehabilitation
Rachel Brandt, MS, CGC	Risk Assessment and Genetic Testing
Mary Burke, MD	Hematology/Medical Oncology
David Craig, PharmD	Pharmacy
Albert DeNittis, MD	Radiation Oncology
Deborah Dickerson, RHIT, CTR	Oncology Data Services
Rene J. Donnard	Marketing/Communications/Public Affairs
Charles Dunton, MD	Gynecologic Oncology
Robert M. Etemad, MD	Gastroenterology
Eileen German, RN, MBA	Quality Improvement
Paul Gilman, MD	Hematology/Medical Oncology
Michael Hagg, MD	Urology
Maria Hendricks, MSN, RN, CCRP	Oncology Research/CCOP
Barry D. Mann, MD	General Surgery
John Marks, MD	Gastroenterology
Thomas Meyer, MD	Pulmonary Diseases/Critical Care
Tracy Mione, OTR/L	Physical Medicine and Rehabilitation
Kathy Moss, RN, BS, OCN	Nursing
Jeannette Nazarian, OTR/L	Physical Medicine and Rehabilitation
Patricia Nogar	Community Services
Sharon L. Nutter, RHIA,CTR	Oncology Data Services
Clifford Pemberton, MD	Hematology/Oncology
Maria Panoc, MT(ASCP), MBA	Administration
Patrice Romanofsky, MSW, LSW	Social Services
Mary Schmidt	Marketing/Communications/Public Affairs
Mary C. Sonke	American Cancer Society
Michelle M. Stewart	Marketing
Constance Sutilla, MD	Radiology
Carla Thomas, MSPH, RHIA, CTR	Oncology Data Services
Rosemarie Tucci, MSN, AOCN	Oncology Research & Data Services
Carol Westbrook	Quality Improvement
Vlasta Zemba-Palko, MD	Pathology

Lankenau Medical Center Cancer Service Directory

Breast Cancer Support Group
484.476.8503

Information, education, and support for women recovering from Breast Cancer.

Breast Evaluation Program
610.645.2494

Weekly multidisciplinary discussion group ensures comprehensive individualized care.

Cancer Risk Assessment and Genetic Testing Program
484.476.8150

Offers genetic assessment, counseling, and testing for high-risk individuals.

Chemotherapy
610.645.2494

Advanced, comprehensive, state–of-the–art treatment to manage cancer in the community setting.

Clinical Trials and Cancer Prevention Research
484.476.2649

Provides patients access to NCI-sponsored clinical research and prevention trials.

Community Education and Screening
484.476.8555

Provides education programs and cancer screenings to the community.

General Cancer Support Caring and Sharing
484.476.8503

Network Support Group Meeting on the fourth (4th) Monday at 3:00-4:00pm in the months of January, March, May, July, September, and November.

"Look Good, Feel Better" Program
484.476.8503

American Cancer Society program providing cosmetic instruction for women diagnosed with cancer.

Lung Cancer
484.476.3339

Multidisciplinary approach to the diagnosis and treatment of lung cancer.

Lymphedema Management Program
484.829.6114

Provides early and continuing treatment for patients with lymphedema.

Oncology Data Services
484.476.8045

A comprehensive data management system for collection of malignant or neoplastic diseases. Oncology Data Specialists capture a complete clinical and demographic summary of the patients' history and treatment and provide lifetime follow-up.

Oncology Social Services
484.476.8503

Social workers providing psychosocial support and counseling for patients and their families.

Physical Medicine and Rehabilitation
484.476.2499

Advice and instruction concerning exercises and/or ambulation for patients undergoing treatment.

Prostate Cancer Support Group
484.476.8503

A monthly networking group for men diagnosed with Prostate Cancer, designed to provide education, support and encouragement.

Radiation Oncology
484.476.2433

Advanced, comprehensive, state-of-the-art treatment to manage cancer in the community setting.

Women's Health Source
1.888.876.8764

A free membership club offering information on a wide variety of health issues important to women.

100 East Lancaster Avenue
Wynnewood, PA 19096

1.866.CALL.MLH
mainlinehealth.org

Lankenau Medical Center
Main Line Health

Well ahead.℠

Membership on the medical staff of Main Line Hospitals does not constitute an employment or agency relationship.

LMC03-11DL05